Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

This review summarizes traditional and emerging therapies for SLE. Evidence suggests that the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials for new targeted therapies. A clearer understanding of the mechanisms driving disease pathogenesis combined with recent advances in medical science are predicted to enable accelerated progress towards improved SLE diagnosis and personalized approaches to treatment.

Original languageEnglish (US)
Pages (from-to)i100-i113
JournalRheumatology (Oxford, England)
Volume56
Issue number1
DOIs
StatePublished - Apr 1 2017

Fingerprint

Therapeutic Human Experimentation
Systemic Lupus Erythematosus
Clinical Trials
Therapeutics

Keywords

  • B cells
  • biological therapies
  • clinical trials and methods
  • immunotherapy
  • systemic lupus erythematosus and autoimmunity

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. / Davis, Laurie S.; Reimold, Andreas M.

In: Rheumatology (Oxford, England), Vol. 56, No. 1, 01.04.2017, p. i100-i113.

Research output: Contribution to journalReview article

@article{0ccbdbc8fa184c87bb2fc7567210d04e,
title = "Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus",
abstract = "This review summarizes traditional and emerging therapies for SLE. Evidence suggests that the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials for new targeted therapies. A clearer understanding of the mechanisms driving disease pathogenesis combined with recent advances in medical science are predicted to enable accelerated progress towards improved SLE diagnosis and personalized approaches to treatment.",
keywords = "B cells, biological therapies, clinical trials and methods, immunotherapy, systemic lupus erythematosus and autoimmunity",
author = "Davis, {Laurie S.} and Reimold, {Andreas M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1093/rheumatology/kew417",
language = "English (US)",
volume = "56",
pages = "i100--i113",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus

AU - Davis, Laurie S.

AU - Reimold, Andreas M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - This review summarizes traditional and emerging therapies for SLE. Evidence suggests that the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials for new targeted therapies. A clearer understanding of the mechanisms driving disease pathogenesis combined with recent advances in medical science are predicted to enable accelerated progress towards improved SLE diagnosis and personalized approaches to treatment.

AB - This review summarizes traditional and emerging therapies for SLE. Evidence suggests that the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials for new targeted therapies. A clearer understanding of the mechanisms driving disease pathogenesis combined with recent advances in medical science are predicted to enable accelerated progress towards improved SLE diagnosis and personalized approaches to treatment.

KW - B cells

KW - biological therapies

KW - clinical trials and methods

KW - immunotherapy

KW - systemic lupus erythematosus and autoimmunity

UR - http://www.scopus.com/inward/record.url?scp=85021854021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021854021&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kew417

DO - 10.1093/rheumatology/kew417

M3 - Review article

VL - 56

SP - i100-i113

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 1

ER -